Nona Biosciences, a wholly owned subsidiary of HBM Holdings Ltd., has entered into a collaboration agreement with Dragonfly Therapeutics Inc. based on Nona's proprietary fully human heavy chain only antibody (HCAb) transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.